BAY 3401016
Alternative Names: BAY-3401016Latest Information Update: 06 Jul 2023
Price :
$50 *
At a glance
- Originator Bayer
- Developer Bayer; Evotec SE
- Class Antibodies
- Mechanism of Action Semaphorin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hereditary nephritis
- Preclinical Acute kidney injury
Most Recent Events
- 29 Jun 2023 Phase-I clinical trials in Hereditary nephritis in Germany (unspecified route)
- 20 Jan 2023 Preclinical trials in Acute kidney injury in Germany (unspecified route) in January 2023 (Bayer pipeline, January 2023)
- 20 Jan 2023 Preclinical trials in Hereditary nephritis in Germany (unspecified route) before January 2023 (Bayer pipeline, January 2023)